期刊文献+

抗癫痫药物群体药动学模型及其临床应用的研究进展 被引量:2

下载PDF
导出
摘要 癫痫是临床常见疾病,抗癫痫药在临床应用频繁。抗癫痫药物的药代动力学复杂,个体差异大,体内代谢受诸多因素影响。因此,在用药时需建立个体化给药方案,而个体化给药的前提就是要知道患者理想的药动学参数。综合比较各种研究方法,用NONMEM法建立的药物群体药动学模型有着突出的优点,国外用此法研究抗癫痫药的群体药动学相对较多,而国内尚较少。
作者 陈荣
出处 《中国民康医学》 2012年第16期2021-2022,2033,共3页 Medical Journal of Chinese People’s Health
  • 相关文献

参考文献11

  • 1Sheiner LB,Grasela TH.An introduction to mixed effect modeling:concepts,definitions,and justification[J].J Pharmacokinet Biop-harm,1991,19(3):11S.
  • 2Grasela TH,Antal EJ,Townsend RJ,et al.An evaluation of popula-tion pharmacokinetics in therapeutic trials,partⅠ[J].Comparision of methodologies Clin Pharmacol Ther,1986,39:605.
  • 3Yukawa E,Hiquchi S,Aoyama T.Population pharmacokinetics of phenytoin from routine clinical data in Japan[J].J Clin Pharm T-her,1989,14(1):71-77.
  • 4Grasela TH,Sheiner LB.Pharmacostatistical modeling for observa-tional data[J].J Pharmacokinet Biopharm,1991,19(3):25S.
  • 5White DB,Walawander CA,Tung Y,et al.An evaluation of point and interval estimates in population pharmacokinetics using NON-MEM analysis[J].J Pharmacokinet Biopharm,1991,19(1):87.
  • 6Powers JD.Statistical considerations in pharmacokinetic study de-sign[J].Clin Pharmacokinet,1993,24(5):380.
  • 7Yukawa E,Nomiyama N,Higuchi S,et al.Lithium population phar-macokinetics from routine clinical data:role of patient characteristicsfor estimating dosing regimens[J].Ther Drug M on it,1993,15(2):75.
  • 8胡敏,张静华,孙鹤,施孝金,俞丽云,钟明康.NONMEM法估算3种抗癫痫药对丙戊酸相对清除率的影响[J].中国药学杂志,2002,37(3):201-205. 被引量:9
  • 9焦正,钟明康,施孝金,胡敏,李中东,王大猷,张莉莉,张静华,王宏图.NONMEM法估算中国癫痫患者卡马西平的清除率[J].中国药理学通报,2003,19(3):314-318. 被引量:11
  • 10胡敏,张静华,孙鹤,施孝金,俞丽云.非线性混合效应模型法估算门诊癫痫患者丙戊酸的相对清除率[J].中国临床药学杂志,2000,9(1):33-36. 被引量:12

二级参考文献23

  • 1陈新谦 金有豫.新编药物学(第14版)[M].北京:人民卫生出版社,1997.487.
  • 2[1]Bertilsson L,Tomson T. Clinical Pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. A update. Clin Pharmacokinet, 1986;11(3):197~8
  • 3[2]Guidance for Industry population pharmacokinetics. Feb 1999, FDA, http://www.fda.gov/ohrms/dockets/98fr/970383gd.pdf. 2001-12-30 last visited
  • 4[4]Wade JR, Kelman AW, Howie CA et al. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. Journal of pharmacokinetics and biopharmaceutics, 1993;2(21):209~22
  • 5[6]Yukawa E, Aoyama T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol, 1996;36(8):752~9
  • 6[7]Gray AL, Botha JH, Miller R. A model for the determination of carbamazepine clearance in children on mono- and polytherapy. Eur J Clin Pharmacol, 1998;54(4):359~62
  • 7[8]Graves NM, Brundage RC, Wen Y et al. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy, 1998;18(2):273~81
  • 8[9]Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol, 2001;51(6):567~76
  • 9[10]Delgado-Iribarnegarary MF, Santos-Buelga D, Garcia-Sanchez MJ et al. Carbamazepine population pharmacokinetics in children: Mixed-effect models. Ther Drug Monit, 1997;19(2):132~9
  • 10[11]Reith DM, Hooper WD, Parke J, Charles B. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinet Biopharm, 2001;28(1):79~92

共引文献40

同被引文献23

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部